🏅 FDA Orphan Designation
Oxervate
cenegermin-bkbj
Manufacturer: Dompe S.p.A.
Indicated for:
Neurotrophic keratopathyOrphan
FDA-Approved Indications (1)
Neurotrophic keratopathyOrphan Designation
Treatment of neurotrophic keratitis
Indications & Usage
1 INDICATIONS AND USAGE OXERVATE ® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis. OXERVATE is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis. ( 1 )
💙 Support Programs
View all →Oxervate
Dompe S.p.A.
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.